Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.